Results of cisplatin, adriamycin and etoposide chemotherapy in patients with recurrent and metastatic endometrial cancer

The efficacy of the combination treatment of cisplatin, adriamycin and etoposide were retrospectively evaluated in 26 recurrent or metastatic endometrial cancer patients. One hundred and twenty-three treatment courses were observed. Patients received 20 mg/m2 cisplatin and 80 mg/m2 etoposide by continuous i.v. infusion for three days and adriamycin 40 mg/m2 i.v. the second day. Treatment courses were repeated every four weeks. Megestrol acetate, 160 mg/day, was added in six patients who had positive progesterone receptors. Ten (38.5%) women had complete and three (11.5%) patients had partial response with an overall response rate of 50%. Median follow-up was 24 months. Surviving patients were alive for four months and six years. Toxicity was mainly hematological and gastrointestinal ulcerations and stomatitis were also observed.

Endometrial cancer; Chemotherapy; Cisplatin; Adriamycin; Etoposide

[1] Thigpen T., Vance R.B., Khansur T.: "The platinum compounds and paclitaxel in the management carcinomas of the endometrium and uterine cervix". Semin. Oncol., 1995, 22 (suppl.), 67S.

[2] Elit L., Hirte H.: "Novel strategies for systemic treatment of endometrial cancer". Expert Opin. Investig. Drugs, 2000, 9, 2831.

[3] Pierga J.Y., Dieras V., Beuzeboc P., Dorval T., Palangie T., Jouve M et al.: "Phase 11 trial of doxorubicin, 5-fluorouracil, etoposide, and ci splatin in advanced or recurrent endometrial carcinoma". Gynecol Oneal., 1997, 66, 246.

[4] Cornelison T.L., Baker T.R., Piver M.S., Driscoll D.L.: "Cisplatm, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma". Gynecol. Oneal., 1995, 59, 243.

[5] Lissoni A., Gabriele A., Gorga G., Tumolo S., Landoni F., Mangioni C., Sessa C.: "Cisplatin, epirubicin and paclitaxel containing chemotherapy in uterine adenocarcinoma". Ann. Oneal., 1997, 8, 969.

[6] Gebbia V., Testa A., Borsellino N.. Ferrera P., Tirrito M., Palmen S.: "Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen". Ann. Oneal., 2001, 12, 767.

[7] Gadducci A., Romanini A., Cosio S., Fanucchi A., Tanganelli L., Ciam B., Genazzani A.R.: "Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study". Anticancer Res., 1999, 19, 2253.

[8] Fung M.F., Krepart G.V., Lotocki R.J., Heywood M.: "Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide and medroxyprogesterone acetate". Obstet. Gynecol., 1991, 78, 1033.